Trial Profile
A Phase 1 Study of LY2801653 in Patients With Advanced Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Merestinib (Primary) ; Cetuximab; Cisplatin; Gemcitabine; Ramucirumab
- Indications Adenocarcinoma; Carcinoma; Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer; Gastric cancer; Head and neck cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer; Uveal melanoma
- Focus Adverse reactions; First in man
- Sponsors Eli Lilly and Company
- 23 Oct 2017 Status changed from active, no longer recruiting to completed.
- 21 Sep 2017 Planned End Date changed from 17 May 2018 to 17 Oct 2018.
- 21 Sep 2017 Planned primary completion date changed from 17 May 2018 to 17 Oct 2018.